Griscelli Syndrome Type 2 C1868679
A rare immune deficiency linked to pigment changes and immune dysfunction. Features include silvery hair, recurrent infections, and risk of severe immune complications like hemophagocytic syndrome. Requires careful monitoring.
Key facts at a glance
- ICD-10
- D89.9
- ICD-11
- 3A00.0
- Body system
- immunologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Hemophagocytic lymphohistiocytosis (HLH) episodes
Generalized symptoms
(immunologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Recurrent pyogenic infections
(immunologic)Partial oculocutaneous albinism (silvery hair)
(skin)Neurological deterioration (developmental regression)
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Drug therapy and clinical monitoring
Active treatment with regular monitoring by a healthcare provider is recommended.
HLH-directed immunomodulation
Aggressive immune suppression using corticosteroids and etoposide-based protocols for hemophagocytic lymphohistiocytosis episodes, which are life-threatening complications of Griscelli syndrome type 2.
Immunodeficiency management
Prophylactic antibiotics and immunoglobulin replacement therapy to prevent and treat recurrent infections characteristic of the underlying immune dysfunction.
Additional treatment options
Allogeneic hematopoietic stem cell transplantation
Curative approach through bone marrow or stem cell transplantation to replace defective immune cells, offering potential resolution of both immunodeficiency and HLH predisposition.
surgicalHLH surveillance and early intervention
Frequent monitoring of HLH biomarkers including ferritin, soluble IL-2 receptor, and clinical signs to enable early detection and prompt treatment of disease flares.
monitoringFamily and caregiver support services
Psychological support for families dealing with chronic serious illness, including counseling, support groups, and assistance navigating complex medical decisions regarding transplantation.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Griscelli Syndrome Type 2 C1868679?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Griscelli Syndrome Type 2 C1868679. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy